Effect of earthworm (G-90) extract on formation and lysis of clots originated from venous blood of dogs with cardiopathies and with malignant tumors.
The stability of homeostasis is important to keep a balance between coagulation and fibrinolysis. A disorder of homeostasis leads to different physiological changes and causes different diseases such as cardiopathies and malignant tumors. Cardiopathies is characterized by a hypercoagulation. In the malignant tumors, besides the hypercoagulation due to plasminogen activators (PA) formed inside the tumor, a disorder of homeostasis leads also to acceleration of the fibrinolysis. The variety of internal and external factors in both cases determine the deviation of time for the clots formation, as well as the lyses of blood and fibrin clots. In this study the venous blood as well as the blood and the fibrin clots, derived from healthy dogs, the dogs with cardiopathies and with malignant tumors, were examined for the time of coagulation and fibrinolysis by adding different substances. In these experiments we used a glycolipoprotein extract from earthworm tissue homogenate (G-90) and the proteolytic enzymes P I and P II, isolated from G-90. The efficacy of the tested substances was comparable with the clinically administered anticoagulants. The most significant differences in clotting time among the three tested groups of dogs were obtained by application of the original G-90. The results suggest a possibility that G-90, along with the fibrinolytic enzymes and other biologically active factors, also contains a factor that decelerates the formation of clot in a specific medium, such as the blood from the dogs with malignant tumors.
Popović
M
M
Department of Biology, Faculty of Veterinary Medicine, Ruder Bockovic Institute, Heinzelova 55, 10000 Zagreb, Croatia. mpopovic@vef.hr
Hrcenjak
T M
TM
Babić
T
T
Kos
J
J
Grdisa
M
M
D000818:Animals; D001780:Blood Coagulation Tests; D002311:Cardiomyopathy, Dilated / Q000662:veterinary*; D004283:Dog Diseases / Q000097:blood*; D004285:Dogs; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D006023:Glycoproteins / Q000494:pharmacology; D015674:Mammary Neoplasms, Animal / Q000097:blood*; D009835:Oligochaeta / Q000737:chemistry*; D013300:Streptokinase / Q000378:metabolism; D014020:Tissue Extracts / Q000302:isolation & purification / Q000494:pharmacology*; D014680:Veins
D005343:Fibrinolytic Agents; D006023:Glycoproteins; D014020:Tissue Extracts; D013300:Streptokinase